The liquid formulation was withdrawn because of an upward trend in spontaneous reports of adverse reactions, including syncope (fainting), which are temporally correlated with a change that was made to the formulation around April 2007 to include edetate disodium (EDTA). The upward trend in adverse reaction reporting rates had not been observed with the use of lyophilized sargramostim. The original liquid formulation without EDTA was returned to the market in the US in May 2008.In 2009, Genzyme acquired the rights to Leukine from Bayer, including the manufacturing facility in the Seattle area.In March 2018 the label was extended to use as a countermeasure for acute radiation syndrome. == References ==
Anyone taking phenelzine should inform their dentist before proceeding with dental surgery, and surgeon in any other contexts. Phenelzine has also been linked to vitamin B6 deficiency. Transaminases such as GABA-transaminase have been shown to be dependent upon vitamin B6 and may be involved in a potentially related process, since the phenelzine metabolite phenylethylidenehydrazine (PEH) is a GABA transaminase inhibitor. Both phenelzine and vitamin B6 are rendered inactive upon these reactions occurring. For this reason, it may be recommended to supplement with vitamin B6 while taking phenelzine. The pyridoxine form of B6 is recommended for supplementation, since this form has been shown to reduce hydrazine toxicity from phenelzine and, in contrast, the pyridoxal form has been shown to increase the toxicity of hydrazines. Research
Phenelzine showed promise in a phase II clinical trial from March 2020 in treating prostate cancer. Phenelzine has also been shown to have neuroprotective effects in animal models. History
Synthesis of phenelzine was first described by Emil Votoček and Otakar Leminger in 1932. See also
Phenylethylidenehydrazine
Hydrazine (antidepressant)
Isocarboxazid
Libby Zion Law (a case involving phenelzine and pethidine)
Monoamine oxidase inhibitor
Tranylcypromine

References
External links
"Phenelzine". Drug Information Portal. U.S. National Library of Medicine.